Record Q2 revenue and strong Sephience launch drove raised 2026 guidance, with robust U.S. and international uptake and over $2.2B in cash. Strategic refinancing, positive clinical progress, and disciplined expense management position the company for sustained growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.